enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment

Rhea-AI Summary

enVVeno Medical (NASDAQ: NVNO) announced that CEO Robert Berman participated in a Virtual Investor “What This Means” segment to discuss two recent milestones for the company’s enVVe replacement venous valve system. He highlighted the issuance of the first U.S. patent covering the enVVe system, which expands enVVeno Medical’s intellectual property portfolio.

Berman also discussed the company’s progress with what he described as the first FDA-approved pivotal trial for a non-surgical replacement venous valve targeting deep chronic venous insufficiency. According to enVVeno Medical, these milestones are intended to form key elements of its strategy to build shareholder value, strengthen its long-term competitive position, and reinforce barriers to entry around its technology. The company further stated that it views the replacement venous valve space as a large, untapped commercial opportunity and believes enVVe has the potential to transform the treatment paradigm. The Virtual Investor segment is now available online.

Positive

• First U.S. patent issued covering the enVVe replacement venous valve system
• Company advancing what it describes as the first FDA-approved pivotal trial for a non-surgical replacement venous valve
• Intellectual property portfolio expanded to support barriers to entry around enVVe technology
• Management presents these milestones as foundational to its strategy to build shareholder value

Negative

• None.

News Market Reaction – NVNO

-1.28%

-1.28% Session close to close

In the Jul 15 session, NVNO declined 1.28%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Against a backdrop where 3 of the last 5 NVNO news items aligned positively with the stock and short...

Analysis

Against a backdrop where 3 of the last 5 NVNO news items aligned positively with the stock and short interest remains categorized as low, this investor segment on the patent and pivotal trial fits into an ongoing awareness push. Recent insider activity shows net selling of a small share block, so investors may watch for future financing or ownership changes.

Historical Context

5 past events · Latest: Jul 07 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 07	Patent issuance	Positive	-0.7%	New U.S. patent covering core enVVe system components and delivery design.
Jun 22	Investor webinar	Positive	+5.0%	Webull webinar highlighting FDA IDE approval and upcoming pivotal enVVe trial.
Jun 02	Investor event	Positive	+0.7%	Virtual Investor event to discuss recent FDA IDE approval and take Q&A.
May 12	IDE discussion segment	Positive	-5.7%	Virtual Investor segment explaining implications of first-ever IDE for venous valve.
May 07	1Q26 earnings report	Positive	+1.5%	Q1 2026 results with $24.9M cash and runway guidance into Q3 2027.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent NVNO news has produced mixed but generally modest moves, with slightly more aligned than divergent reactions to positive catalysts.

Key Terms

ide, pivotal trial, deep chronic venous insufficiency

3 terms

ide regulatory

"First-Ever FDA IDE Approval, Positions enVVe"

An IDE (Investigational Device Exemption) is a regulatory permission that allows a company to test an unapproved medical device in human clinical trials to gather safety and effectiveness data. Think of it as a temporary road permit for a new product: getting the IDE moves a technology from concept toward approval and market access, which can reduce uncertainty and increase value for investors, while delays or denials raise development risk and potential costs.

pivotal trial medical

"advancing the first FDA-approved pivotal trial for a non-surgical replacement venous valve"

A pivotal trial is a key test of a new medicine or treatment to see if it works and is safe enough to be approved by health authorities. It's like a final exam for a new product, and passing it is essential for bringing the treatment to the public.

deep chronic venous insufficiency medical

"transform the treatment paradigm for deep chronic venous insufficiency."

A long-term condition in which leg veins fail to move blood efficiently back to the heart, causing swelling, pain, skin changes and sometimes open sores; “deep” indicates involvement of the larger, deeper veins rather than just surface veins. It matters to investors because its chronic, severe nature drives demand for medical devices, pharmaceuticals, surgical procedures and long-term care, and influences healthcare costs, reimbursement decisions and regulatory approvals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe® to Own a Multi-Billion-Dollar Venous Disease Market

Watch the "What This Means" video here

IRVINE, CA / ACCESS Newswire / July 15, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical participated in a Virtual Investor "What This Means" segment.

As part of the segment, Mr. Berman discussed the Company's recent news announcing the issuance of the first U.S. Patent covering the company's enVVe system, further expanding its intellectual property portfolio and laying the groundwork to dominate the large and untapped replacement venous valve market.

"Receiving a foundational U.S. patent while simultaneously advancing the first FDA-approved pivotal trial for a non-surgical replacement venous valve are both important fundamental parts of our strategy to build shareholder value," said Robert Berman, Chief Executive Officer of enVVeno Medical. "In this discussion, we explain why we believe these milestones significantly strengthen our long-term competitive position, reinforce the barriers to entry around our technology, and position the Company to pursue what we believe is a substantial commercial opportunity. We encourage investors to watch the segment to better understand why we believe enVVe has the potential to transform the treatment paradigm for deep chronic venous insufficiency."

The Virtual Investor "What This Means" segment featuring enVVeno Medical is now available here.

About enVVeno Medical Corporation

enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.

Cautionary Note on Forward-Looking Statements

This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

INVESTOR CONTACT:

JTC Team, LLC
Jenene Thomas
NVNO@jtcir.com
(908) 824-0775

SOURCE: enVVeno Medical Corporation

View the original press release on ACCESS Newswire

FAQ

What patent did enVVeno Medical (NASDAQ: NVNO) highlight in July 2026?

enVVeno Medical highlighted issuance of the first U.S. patent covering its enVVe replacement venous valve system. According to enVVeno Medical, this patent broadens its intellectual property portfolio and is viewed as a foundational element of its strategy in the replacement venous valve market.

How does the new U.S. patent support enVVeno Medical’s enVVe pivotal trial for NVNO?

The patent provides broad protection for the enVVe system while the pivotal trial advances in the U.S. According to enVVeno Medical, combining patent coverage with the FDA-approved pivotal trial strengthens its competitive position and supports its long-term commercialization strategy for replacement venous valves.

What is enVVe and what condition is enVVeno Medical targeting with NVNO?

enVVe is a non-surgical replacement venous valve system being developed for deep chronic venous insufficiency. According to enVVeno Medical, the device is in an FDA-approved pivotal trial and is aimed at transforming the treatment paradigm in this large and currently undertreated venous disease area.

Why does enVVeno Medical believe NVNO can address a multi-billion-dollar venous disease market?

The company believes broad patent protection and its first FDA-approved pivotal trial position enVVe for a substantial commercial opportunity. According to enVVeno Medical, the replacement venous valve market is large and untapped, and enVVe could help the company compete for this multi-billion-dollar segment.

What did enVVeno Medical’s CEO discuss in the July 2026 Virtual Investor "What This Means" segment for NVNO?

CEO Robert Berman discussed the newly issued U.S. patent for enVVe and the ongoing FDA-approved pivotal trial. According to enVVeno Medical, he explained why these milestones may strengthen the company’s long-term competitive position and support its strategy to build shareholder value.

Where can investors watch enVVeno Medical’s July 15, 2026 Virtual Investor segment about NVNO?

Investors can watch the Virtual Investor “What This Means” segment featuring enVVeno Medical online via the referenced video link. According to enVVeno Medical, the segment explains how the U.S. patent and pivotal trial relate to the enVVe system and its commercial potential.